Results

eNauka >  Rezultati >  Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
Naziv: Afatinib in locally advanced/metastatic NSCLC harboring common <i>EGFR</i> mutations, after chemotherapy: a Phase IV study
Autori: Thongprasert, Sumitra; Geater, Sarayut L; Clement, Dana; Abdelaziz, Amr; Reyes-Igama, Jasmin; Jovanovic, Dragana; Alexandru, Aurelia; Schenker, Michael; Sriuranpong, Virote; Serwatowski, Piotr;
Godina: 2019
Publikacija: LUNG CANCER MANAGEMENT
ISSN: 1758-1966 Lung Cancer Management Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 8 br. 3
DOI: 10.2217/lmt-2019-0004
WoS-ID: 000511920100002
URI: https://enauka.gov.rs/handle/123456789/992287
Projekat: AstraZeneca
Roche
Boehringer Ingelheim
Novartis
Astra Zeneca
Astellas
Bristol Myers Squibb
Eli Lilly
Pfizer
AbbVie
Merck
Merck Serono
Bioven
Pharma Mar
Regeneron
Eisai
Amgern
Mylan
Izvor metapodataka: (Preuzeto iz Nasi u WoS)
M-kategorija: 
Mp kategorija će biti prikazana naknadno.

3
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.